Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for aggressive brain tumors: Triple-Drug attack shows promise

NCT ID NCT05463848

First seen Mar 08, 2026 · Last updated Apr 30, 2026 · Updated 10 times

Summary

This study tests a combination of three drugs (pembrolizumab, olaparib, and temozolomide) in people whose glioblastoma brain tumor has come back after prior treatment. The goal is to see if this mix can shrink the tumor or slow its growth by boosting the immune system and damaging cancer cells. About 78 adults will take part, and researchers will measure how long the cancer stays under control and how well the immune system responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

Conditions

Explore the condition pages connected to this study.